DDInter1619 DDInter1626
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label],. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole.
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
Ropinirole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rucaparib
Ropinirole {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rucaparib
Ropinirole {u} (Compound) causes {v} (Side Effect) Bursitis
Bursitis {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rucaparib
Ropinirole {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropinirole {u} (Compound) causes {v} (Side Effect) Bursitis
Bursitis {u} (Side Effect) is caused by {v} (Compound) Eszopiclone
Eszopiclone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropinirole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Eszopiclone
Eszopiclone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropinirole {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Ropinirole {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Ropinirole {u} (Compound) causes {v} (Side Effect) Bursitis
Bursitis {u} (Side Effect) is caused by {v} (Compound) Tizanidine
Tizanidine {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Ropinirole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dolasetron
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Ropinirole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Ropinirole (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Ropinirole (Compound) causes Bursitis (Side Effect) and Bursitis (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Ropinirole (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropinirole (Compound) causes Bursitis (Side Effect) and Bursitis (Side Effect) is caused by Eszopiclone (Compound) and Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropinirole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Eszopiclone (Compound) and Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropinirole (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Ropinirole (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Rucaparib
Ropinirole (Compound) causes Bursitis (Side Effect) and Bursitis (Side Effect) is caused by Tizanidine (Compound) and Tizanidine may lead to a major life threatening interaction when taken with Rucaparib
Ropinirole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dolasetron (Compound) and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib